Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Brigham & Women's Hospital, Boston, Massachusetts.
Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Gastroenterology. 2021 Jul;161(1):143-150.e4. doi: 10.1053/j.gastro.2021.03.039. Epub 2021 Mar 29.
BACKGROUND & AIMS: Lynch syndrome (LS) is associated with increased risks of various gastrointestinal, gynecologic, genitourinary, and other cancers. Many clinical practice guidelines recommend that LS carriers' screening strategies be devised based on their family history of various cancers, in addition to age-, sex-, and gene-specific considerations. The aim of this study was to examine the association between family history and other clinical factors with LS carriers' histories of various cancers.
Two cohorts of LS carriers were analyzed: a laboratory-based cohort of consecutively ascertained individuals undergoing germline LS testing and a clinic-based cohort of LS carriers undergoing clinical care at an academic medical center. Multivariable logistic regression was performed to assess clinical factors associated with LS carriers' histories of various cancers/neoplasms. Familial burden was defined as LS carriers' aggregate number of first-/second-degree relatives with a history of a given malignancy.
Multivariable analysis of the laboratory-based cohort (3828 LS carriers) identified familial burden as being incrementally associated with LS carriers' personal history of endometrial (odds ratio [OR], 1.37 per affected first-/second-degree relative; 95% confidence interval [CI], 1.21-1.56), urinary tract (OR, 2.72; 95% CI, 2.02-3.67), small bowel (OR, 3.17; 95% CI, 1.65-6.12), gastric (OR, 1.93; 95% CI, 1.24-3.02), and pancreaticobiliary cancers (OR, 2.10; 95% CI, 1.21-3.65) and sebaceous neoplasms (OR, 7.39; 95% CI, 2.71-20.15). Multivariable analysis of the clinic-based cohort (607 LS carriers) confirmed a significant association of familial burden of endometrial and urinary tract cancers.
Familial burden - in addition to age, sex, and specific LS gene - should be used to assess LS carriers' risks of specific cancers and guide decision-making about organ-specific surveillance.
林奇综合征(LS)与多种胃肠道、妇科、泌尿生殖和其他癌症的风险增加有关。许多临床实践指南建议,除了年龄、性别和基因特异性考虑外,还应根据 LS 携带者的家族史制定各种癌症的筛查策略。本研究旨在探讨家族史和其他临床因素与 LS 携带者各种癌症病史的关系。
对两个 LS 携带者队列进行了分析:一个是通过连续确定的正在进行种系 LS 检测的实验室队列,另一个是在学术医疗中心进行临床护理的 LS 携带者的临床队列。采用多变量逻辑回归评估与 LS 携带者各种癌症/肿瘤病史相关的临床因素。家族负担定义为 LS 携带者的一级和二级亲属中患有某种恶性肿瘤的总人数。
对实验室队列(3828 名 LS 携带者)进行的多变量分析发现,家族负担与 LS 携带者的子宫内膜癌个人病史呈递增关系(比值比 [OR],每有一个受影响的一级或二级亲属增加 1.37;95%置信区间 [CI],1.21-1.56)、泌尿道(OR,2.72;95%CI,2.02-3.67)、小肠(OR,3.17;95%CI,1.65-6.12)、胃(OR,1.93;95%CI,1.24-3.02)和胰腺胆道癌(OR,2.10;95%CI,1.21-3.65)和皮脂肿瘤(OR,7.39;95%CI,2.71-20.15)。对临床队列(607 名 LS 携带者)的多变量分析证实,家族子宫内膜癌和泌尿道癌负担与显著相关。
除了年龄、性别和特定的 LS 基因外,家族负担也应用于评估 LS 携带者特定癌症的风险,并指导关于特定器官监测的决策。